title: Usefulness of omalizumab in ten patients with severe occupational asthma.
abstract: BACKGROUND
  The management of severe occupational asthma (OA) remains problematic and new alternative treatments providing better disease control are required, ideally enabling affected individuals to remain in their job.
  
  
  METHODS
  Ten patients with severe uncontrolled OA were treated with the monoclonal anti-IgE antibody omalizumab. In six cases the causative agent was a high molecular weight (HMW) compound and in four cases it was a low molecular weight (LMW) chemical. All of the patients had well documented OA despite workplace adjustments.
  
  
  RESULTS
  During treatment, nine patients exhibited a lower rate of asthma exacerbations and used less oral or inhaled corticosteroids. Seven patients were able to continue working at the same workplace as before treatment.
  
  
  CONCLUSIONS
  We have demonstrated that omalizumab is a potential treatment for severe uncontrolled OA and enabled seven of the ten patients in the study to remain in their job.
authors: Maladies Respiratoires et Allergiques, CHU, Reims, France. lavaud.francois@wanadoo.fr
authors: F
authors: F
authors: Lavaud
authors: P
authors: P
authors: Bonniaud
authors: J C
authors: JC
authors: Dalphin
authors: C
authors: C
authors: Leroyer
authors: D
authors: D
authors: Muller
authors: R
authors: R
authors: Tannous
authors: G
authors: G
authors: Mangiapan
authors: F
authors: F
authors: De Blay
mesh_terms: D000328:Adult; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D059366:Asthma, Occupational / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D000069444:Omalizumab; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D018927:Anti-Asthmatic Agents; D000888:Antibodies, Anti-Idiotypic; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab